111 related articles for article (PubMed ID: 32246555)
1. Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors.
Zhang D; Zheng Y; Lin Z; Liu X; Li J; Yang H; Tan W
Angew Chem Int Ed Engl; 2020 Jul; 59(29):12022-12028. PubMed ID: 32246555
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma.
Zheng Y; Lai Z; Wang B; Wei Z; Zeng Y; Zhuang Q; Liu X; Lin K
Discov Oncol; 2023 Sep; 14(1):164. PubMed ID: 37665421
[TBL] [Abstract][Full Text] [Related]
3. Surface Engineering of Natural Killer Cells with CD44-targeting Ligands for Augmented Cancer Immunotherapy.
Kim S; Li S; Jangid AK; Park HW; Lee DJ; Jung HS; Kim K
Small; 2024 Jun; 20(24):e2306738. PubMed ID: 38161257
[TBL] [Abstract][Full Text] [Related]
4. NK-92 cells labeled with Fe
Lian J; Li M; Duan M; Sun Y; Wang Z; Guo X; Li J; Gao G; Li K
J Nanobiotechnology; 2024 Jun; 22(1):313. PubMed ID: 38840120
[TBL] [Abstract][Full Text] [Related]
5. Programmed Remodeling of the Tumor Milieu to Enhance NK Cell Immunotherapy Combined with Chemotherapy for Pancreatic Cancer.
Yang X; Li C; Yang H; Li T; Ling S; Zhang Y; Wu F; Liu X; Liu S; Fan C; Wang Q
Nano Lett; 2024 Mar; 24(11):3421-3431. PubMed ID: 38377170
[TBL] [Abstract][Full Text] [Related]
6. Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy.
Qian H; Fu Y; Guo M; Chen Y; Zhang D; Wei Y; Jin F; Zeng Q; Wang Y; Chai C; Ding S; Cheng W; Chen T
Mol Ther; 2024 Jun; ():. PubMed ID: 38906153
[No Abstract] [Full Text] [Related]
7. In Situ Synthesis of an Aptamer-Based Polyvalent Antibody Mimic on the Cell Surface for Enhanced Interactions between Immune and Cancer Cells.
Shi P; Wang X; Davis B; Coyne J; Dong C; Reynolds J; Wang Y
Angew Chem Int Ed Engl; 2020 Jul; 59(29):11892-11897. PubMed ID: 32307868
[TBL] [Abstract][Full Text] [Related]
8. Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR.
Lin B; Tian T; Lu Y; Liu D; Huang M; Zhu L; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Mar; 60(14):7582-7586. PubMed ID: 33382182
[TBL] [Abstract][Full Text] [Related]
9. Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy.
Yang Y; Sun X; Xu J; Cui C; Safari Yazd H; Pan X; Zhu Y; Chen X; Li X; Li J; Tan W
ACS Nano; 2020 Aug; 14(8):9562-9571. PubMed ID: 32584540
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-Based Detection of Circulating Targets for Precision Medicine.
Wu L; Wang Y; Xu X; Liu Y; Lin B; Zhang M; Zhang J; Wan S; Yang C; Tan W
Chem Rev; 2021 Oct; 121(19):12035-12105. PubMed ID: 33667075
[TBL] [Abstract][Full Text] [Related]
11. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
[TBL] [Abstract][Full Text] [Related]
12. Cytosolic Delivery of Thiolated Neoantigen Nano-Vaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity.
Zhang D; Lin Z; Wu M; Cai Z; Zheng Y; He L; Li Z; Zhou J; Sun L; Chen G; Zeng Y; Li J; Liu J; Yang H; Liu X
Adv Sci (Weinh); 2021 Mar; 8(6):2003504. PubMed ID: 33747739
[TBL] [Abstract][Full Text] [Related]
13. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors.
Yamauchi T; Hoki T; Oba T; Jain V; Chen H; Attwood K; Battaglia S; George S; Chatta G; Puzanov I; Morrison C; Odunsi K; Segal BH; Dy GK; Ernstoff MS; Ito F
Nat Commun; 2021 Mar; 12(1):1402. PubMed ID: 33658501
[TBL] [Abstract][Full Text] [Related]
14. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy.
Au KM; Park SI; Wang AZ
Sci Adv; 2020 Jul; 6(27):eaba8564. PubMed ID: 32923587
[TBL] [Abstract][Full Text] [Related]
15. Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy.
De La Fuente A; Zilio S; Caroli J; Van Simaeys D; Mazza EMC; Ince TA; Bronte V; Bicciato S; Weed DT; Serafini P
Sci Transl Med; 2020 Jun; 12(548):. PubMed ID: 32554710
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-Based Logic Computing Reaction on Living Cells to Enable Non-Antibody Immune Checkpoint Blockade Therapy.
Yang Y; Xu J; Sun Y; Mo L; Liu B; Pan X; Liu Z; Tan W
J Am Chem Soc; 2021 Jun; 143(22):8391-8401. PubMed ID: 34029474
[TBL] [Abstract][Full Text] [Related]
17. Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives.
Li L; Xu S; Yan H; Li X; Yazd HS; Li X; Huang T; Cui C; Jiang J; Tan W
Angew Chem Int Ed Engl; 2021 Feb; 60(5):2221-2231. PubMed ID: 32282107
[TBL] [Abstract][Full Text] [Related]
18. Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy.
Qian H; Fu Y; Guo M; Chen Y; Zhang D; Wei Y; Jin F; Zeng Q; Wang Y; Chai C; Ding S; Cheng W; Chen T
Mol Ther; 2022 Aug; 30(8):2817-2827. PubMed ID: 35450820
[TBL] [Abstract][Full Text] [Related]
19. Aptamers as Versatile Molecular Tools for Antibody Production Monitoring and Quality Control.
Chen K; Zhou J; Shao Z; Liu J; Song J; Wang R; Li J; Tan W
J Am Chem Soc; 2020 Jul; 142(28):12079-12086. PubMed ID: 32516525
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
